Cambrex invests 30 million dollars in new Italian research facility
Global contract manufacturer Cambrex started construction on a 30 million dollar research and development facility at its Milan site in Italy on 11 August 2026 to expand services
Cambrex, a prominent global contract development and manufacturing organization (CDMO), has announced a $30 million investment to build a new research and development (R&D) facility in Milan, Italy. This significant expansion will enhance the company's advanced analytical development and process R&D capabilities, alongside upgrades to existing production plants.
The new facility, expected to be operational in the second half of 2027, will reinforce Cambrex's dedication to supporting the pharmaceutical industry's most intricate small molecule development.
The Milan R&D facility, in its 80th year of operation, boasts a storied history of supporting pharmaceutical development and manufacturing for its global clientele. Recently, Cambrex Milan celebrated this milestone, commemorating eight decades of scientific accomplishment and unwavering commitment to improving human health. Claudio Russolo, Cambrex's Chief Operating Officer, stated, "Breaking ground on this new facility underscores the enduring legacy and expertise of our Milan team.
For 80 years, this site has been a cornerstone of pharmaceutical manufacturing in Europe. With this expansion, we are investing not only in cutting-edge technologies and capabilities but also in the future of our people and our partners."
This investment aligns with Cambrex's legacy of scientific prowess and manufacturing excellence, positioning the company for its forthcoming growth phase. By bolstering R&D capabilities in Milan, Cambrex aims to bolster its prowess in addressing the escalating complexity of today's small molecule therapies.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
